Assessment of Efficacy of Pharmacotherapy for Ventricular Tachycardia

Cooper, Mark J.

doi:10.1016/j.hlc.2007.03.006

Cited by 5 publications

(6 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current first-line treatment for ventricular arrhythmia is therefore often devices and classical anti-arrhythmic drugs as adjuncts (83,84). A detailed description of new attempts is given in the section on pharmacological tools.…”

Section: Atrial and Ventricular Fibrillationmentioning

confidence: 99%

“…In recent years, new developments of K ϩ channel modulators have been sparse as a consequence of the proarrhythmia associated with traditional class III antiarrhythmics and the current first-line treatment with implantable electronic devices (84,86,110,119). However, there have been some preclinical approaches investigating the idea of an increased repolarization reserve as a new principle for treating ventricular arrhythmias.…”

Section: B Strategies For Treatment Of Vfmentioning

confidence: 99%

See 1 more Smart Citation

Cardiac Potassium Channel Subtypes: New Roles in Repolarization and Arrhythmia

Schmitt

Grunnet

Olesen

2014

Physiological Reviews

202

197

View full text Add to dashboard Cite

About 10 distinct potassium channels in the heart are involved in shaping the action potential. Some of the K+ channels are primarily responsible for early repolarization, whereas others drive late repolarization and still others are open throughout the cardiac cycle. Three main K+ channels drive the late repolarization of the ventricle with some redundancy, and in atria this repolarization reserve is supplemented by the fairly atrial-specific KV1.5, Kir3, KCa, and K2P channels. The role of the latter two subtypes in atria is currently being clarified, and several findings indicate that they could constitute targets for new pharmacological treatment of atrial fibrillation. The interplay between the different K+ channel subtypes in both atria and ventricle is dynamic, and a significant up- and downregulation occurs in disease states such as atrial fibrillation or heart failure. The underlying posttranscriptional and posttranslational remodeling of the individual K+ channels changes their activity and significance relative to each other, and they must be viewed together to understand their role in keeping a stable heart rhythm, also under menacing conditions like attacks of reentry arrhythmia.

show abstract

Section: Atrial and Ventricular Fibrillationmentioning

confidence: 99%

Section: B Strategies For Treatment Of Vfmentioning

confidence: 99%

Cardiac Potassium Channel Subtypes: New Roles in Repolarization and Arrhythmia

Schmitt

Grunnet

Olesen

2014

Physiological Reviews

202

197

View full text Add to dashboard Cite

show abstract

“…For example, it has been revealed that the feasibility of nanoparticles vectors that optimal polymer compositions such as molecular weight and pKa can be selected plays a pivotal role in facilitating the release and endosomal escape of pDNA and eventually induces high transfection efficiency [36]. In addition, various shapes of nanoparticles can be achieved by varying the polylysine (PLL) counterion present at the time of compaction [37]. This formulation option helps facilitate the development of customized nanoparticles for use in different cell types.…”

Section: Variable Physicochemical Properties For Gene Loadingmentioning

confidence: 99%

Nanoparticles for Gene Delivery: A Brief Patent Review

Xu¹,

Zhang

2009

DDF

View full text Add to dashboard Cite

Gene therapy, as therapeutic treatment to genetic or acquired diseases, is attracting much interest in the research community, leading to noteworthy developments over the past two decades. Nonviral vectors have recently received an increasing attention in order to overcome the safety problems of viral counterpart. Nanoparticles with their special characteristics such as small particle size, large surface area and the capability of changing their surface properties have numerous advantages compared with other gene delivery systems. This article reviews the advances of nanoparticles in patents for gene delivery and emphasizes methods to promote gene transfection efficiency.

show abstract

“…The background and rationale for this trial are discussed in an accompanying article by Cooper. 59 Subsequently, other investigators 60,61 conducted prospective trials (MADIT and MUSST) in patients with previous myocardial infarction, depressed left ventricular function, non-sustained ventricular tachycardia, and ventricular tachycardia inducible at electrophysiological study. Authors of the MADIT (196 patients) and MUSST (704 patients) trials reported reductions of 54% and 51%, respectively in all-cause mortality in patients randomised to receive a defibrillator.…”

Section: Post-infarction Studies After 1980mentioning

confidence: 99%